Phase 2 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with lupus (SLE):
- Women aged 18 or older who have been diagnosed with lupus meeting specific criteria, and whose disease is mild to moderately active at the time of screening
- If taking steroid medications, the dose must be no more than 20 mg per day and must have been the same dose for at least 4 weeks before screening
- If taking hydroxychloroquine, chloroquine, or quinacrine (anti-malarial drugs used for lupus), the dose must have been stable for at least 12 weeks before screening and must not exceed certain maximum amounts (confirm with trial site)
- If taking immune-suppressing medications such as methotrexate, azathioprine, or similar drugs, the dose must have been stable for at least 12 weeks before screening
- Women who could become pregnant must agree to use effective birth control throughout the study
- Must be willing and able to follow all study procedures and attend all required visits
- Must be willing to follow certain lifestyle guidelines for the duration of the study
- Must be willing and able to read and sign a consent form
- If currently taking vitamin B3 or tryptophan supplements, must be willing to stop taking them at least 6 weeks before the study begins
For healthy comparison participants:
- Women aged 18 or older
- No history of autoimmune or inflammatory disease
- If currently taking vitamin B3 or tryptophan supplements, must be willing to stop at least 6 weeks before the blood draw visit
Who may not be able to join:
For people with lupus (SLE):
- Those with active kidney disease, active nervous system involvement from lupus, or serious kidney or liver problems
- Those who have been treated with certain biologic medications (such as rituximab or belimumab) within the past 6 months
- Those who have recently received cyclophosphamide or IVIG treatment, or had their steroid dose increased within the past 4 weeks
- Women who are pregnant or currently breastfeeding
- Those who have taken part in another clinical trial or received an experimental treatment within the past 6 months
For healthy comparison participants:
- Those who are unable to sign a consent form
- Women who are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rachael J Klein, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Phone: (301) 594-1281
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary end point will be to assess the effect of NR on blunting type I IFN signaling and cytokine secretion from placebo vs. NR supplemented subjects in monocytes comparing baseline (visit 1 to visit 3).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.